TROPION-Breast02 Phase III Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer

Daiichi Sankyo announced that the first patient was dosed in the global TROPION-Breast02 Phase III trial evaluating the efficacy and safety of datopotamab deruxtecan versus investigator’s choice of chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC not eligible to receive PD-1/PD-L1 inhibitor therapy.
[Daiichi Sankyo]
Press Release
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News